Taxus Cardium (CRXM) Announces Biological And Clinical Advances In Angiogenic Gene Therapy For Heart Disease In Journal Of Cardiovascular Pharmacology
8/13/2014 7:42:09 AM
SAN DIEGO--(BUSINESS WIRE)--Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), today announced the publication of a review article entitled “Identifying and Overcoming Obstacles in Angiogenic Gene Therapy for Myocardial Ischemia,” authored by Gabor M. Rubanyi, M.D., Ph.D., Cardium’s Chief Scientific Officer, in the August 2014 issue of Journal of Cardiovascular Pharmacology.
The publication outlines advances in biological and medical knowledge about Generx® [Ad5FGF-4] alferminogene tadenovec angiogenic gene therapy pioneered by Cardium and others for the potential treatment of myocardial ischemia, including mechanistic and biological insights, optimization of clinical trial design, selection of target patient populations and meaningful efficacy endpoints. The publication also reports, for the first time, the results of studies performed by Cardium researchers in collaboration with Essen Biosciences (Ann Arbor, Michigan) demonstrating a synergistic interaction between fibroblast growth factor-4 (FGF-4), the therapeutic gene in Generx, and vascular endothelial growth factor (VEGF) in the promotion of neo-vessel formation. Evidence is presented that FGF controls angiogenesis upstream of VEGF. The abstract of the publication is now available online at the following link: http://journals.lww.com/cardiovascularpharm/Abstract/2014/08000/Identifying_and_Overcoming_Obstacles_in_Angiogenic.1.aspx. The Company will send the full article to interested parties upon request by contacting Cardium at 858-436-1000.
Help employers find you! Check out all the jobs and post your resume.
comments powered by